A peritonealis dialízis jelentősége a vesepótló kezelésben várhatóan növekedni fog, emiatt különösen fontos a peritonealis dialízis technológiájának legfőbb hátrányát jelentő glükózexpozíció újragondolása, az adverz hatások minimálisra csökkentése, amely a PD-oldatok további fejlesztésétől várható. Az első lépést a jelenlegi konvencionális glükózalapú PD-oldatok lokális és szisztémás káros hatásainak csökkentésében a biokompatibilis és nem glükózalapú modern PD-oldatok kifejlesztése jelentette. Egyelőre – limitált tapasztalatok alapján – nincsenek egyértelmű adatok a jobb klinikai kimenetelre. Felmerül az elméleti összefüggés a PD ritka szövődményeként kialakuló enkapszuláló peritonealis sclerosis és a peritonealis felszín lokális tartós glükózirritációja között. A szisztémás glykaemiás terhelés mértéke az aktuális állapotot tükröző szövetiglükóz-monitorozással, a hosszabb távon kialakuló kumulatív károsodás a bőr-autofluoreszcencia mérése útján követhető, a klinikai gyakorlatban azonban egyelőre egyik módszer sem kiterjedten használt. A modalitásból eredően fokozottabb a cardiovascularis betegségek rizikója, ezek mielőbbi diagnosztikája és kezelése kiemelt fontosságú. A diabetológiai szempontokat is tekintetbe vevő terápiás lépések megválasztásakor a páciensek életminőségi mutatóinak javítására, a megvalósítható legoptimálisabb életvitelre kell törekednünk. Orv Hetil. 2017; 158(43): 1708–1714.
Polner K. The past and present of peritoneal dialysis. [A peritoneális dialízis múltja és jelene.] Orv Hetil. 2008; 149: 5–11. [Hungarian]
Ortiz A, Covic A, Fliser D, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014; 383: 1831–1843.
Van de Luijtgaarden MW, Jager KJ, Segelmark M, et al. Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year period. Nephrol Dial Transplant. 2016; 31: 120–128.
Kim YL. Can we overcome the predestined poor survival of diabetic patients? Perspectives from pre- and post-dialysis. Perit Dial Int. 2007; 27(Suppl 2): S171–S175.
Ozener C, Arikan H, Karayaylali I, et al. The impact of diabetes mellitus on peritoneal dialysis: the Turkey Multicenter Clinic Study. Ren Fail. 2014; 36: 149–153.
Qayyum A, Chowdhury TA, Oei EL, et al. Use of continuous glucose monitoring in patients with diabetes mellitus on peritoneal dialysis: correlation with glycated hemoglobin and detection of high incidence of unaware hypoglycemia. Blood Purif. 2016; 41: 18–24.
Zakar G. Dietary treatment in dialysis patients. [Dializált betegek étrendi kezelése.] Hypertonia és Nephrologia 2015; 19(Suppl 3): 57–58. [Hungarian]
Ladányi E, Schneider K, Rikker Cs, et al. Practice of chronic peritoneal dialysis in adulthood. [A krónikus peritoneális dialíziskezelés felnőttkori gyakorlata.] Hypertonia és Nephrologia 2015; 19(Suppl 3): 42–53. [Hungarian]
Farhat K, Stavenuiter AW, Beelen RH, et al. Pharmacologic targets and peritoneal membrane remodeling. Perit Dial Int. 2014; 34: 114–123.
Araújo JE, Jorge S, Teixeira E, et al. A cost-effective method to get insight into the peritoneal dialysate effluent proteome. J Proteomics 2016; 145: 207–213.
Fernández-Reyes MJ, Bajo MA, Del Peso G, et al. The influence of initial peritoneal transport characteristics, inflammation, and high glucose exposure on prognosis for peritoneal membrane function. Perit Dial Int. 2012; 32: 636–644.
Petrie MC, Traynor JP, Mactier RA. Incidence and outcome of encapsulating peritoneal sclerosis. Clin Kidney J. 2016; 9: 624–629.
Loureiro J, Gónzalez-Mateo G, Jimenez-Heffernan J, et al. Are the mesothelial-to-mesenchymal transition, sclerotic peritonitis syndromes, and encapsulating peritoneal sclerosis part of the same process? Int J Nephrol. 2013; 2013: 263285.
Alston H, Fan S, Nakayama M. Encapsulating peritoneal sclerosis. Semin Nephrol. 2017; 37: 93–102.
Brown EA, Bargman J, van Biesen W, et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis – position paper for ISPD: 2017 update. Perit Dial Int. 2017; 37: 362–374.
Hoshino T, Ishii H, Kitano T, et al. Effects of a new bicarbonate/lactate-buffered neutral peritoneal dialysis fluid for peritoneal failure in patients undergoing peritoneal dialysis. Discov Med. 2016; 21: 81–88.
Yamaguchi N, Miyamoto K, Ishikawa E, et al. Newly developed neutralized pH icodextrin dialysis fluid: nonclinical evaluation. Artif Organs 2016; 40: E158–E166.
Chang TI, Ryu DR, Yoo TH, et al., on behalf of the Yonsei Associate Network CHronic Kidney Disease Trial (YACHT) investigators. Effect of icodextrin solution on the preservation of residual renal function in peritoneal dialysis patients: A randomized controlled study. Medicine (Baltimore) 2016; 95: e2991.
Sikaneta T, Wu G, Abdolell M, et al. The Trio Trial – a randomised controlled trial evaluating the effect of a biocompatible peritoneal dialysis solution on residual renal function. Perit Dial Int. 2016; 36: 526–532.
Htay H, Cho Y, Pascoe EM, et al. Predictors of residual renal function decline in peritoneal dialysis patients: The balANZ trial. Perit Dial Int. 2017; 37: 283–289.
Dousdampanis P, Trigka K, Bargman JM. Bimodal solutions or twice-daily icodextrin to enhance ultrafiltration in peritoneal dialysis patients. Int J Nephrol. 2013; 2013: 424915.
Szeto CC, Johnson DW. Low GDP solution and glucose-sparing strategies for peritoneal dialysis. Semin Nephrol. 2017; 37: 30–42.
Qayyum A, Oei EL, Paudel K, et al. Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions. World J Nephrol. 2015; 4: 92–97.
Cho Y, Johnson DW, Craig JC, et al. Biocompatible dialysis fluids for peritoneal dialysis. A Cochrane Database Syst Rev. 2014; (3): CD007554.
Wang AY, Brimble KS, Brunier G, et al. ISPD Cardiovascular And Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II – Management of Various Cardiovascular Complications. Perit Dial Int. 2015; 35: 388–396.
Wen Y, Guo Q, Yang X, et al. High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 2015; 35: 70–77.
Hassan K, Hassan S, Anwar S, et al. Predictors of left ventricular hypertrophy and their cut offs in peritoneal dialysis patients. Int Heart J. 2015; 56: 186–191.
Lambie M, Chess J, Do JY, et al. Peritoneal dialysate glucose load and systemic glucose metabolism in non-diabetics: Results from the GLOBAL Fluid Cohort Study. PLoS One 2016; 11: e0155564.
Meerwaldt R, Hartog JW, Graaf R, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol. 2005; 16: 3687–3693.
Yamagishi S, Fukami K, Matsui T, et al. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. Int J Cardiol. 2015; 185: 263–268.
Smit AJ, Smit JM, Botterblom GJ, et al. Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes. PLoS One 2013; 8: e65592.
DiagnOptics website. Available from: http://www.diagnoptisc.com/advanced-glycation-endproducts/measuring-ages
Nongnuch A, Davenport A. Skin autofluorescence advanced glycosylation end products as an independent predictor of mortality in high flux haemodialysis and haemodialysis patients. Nephrology (Carlton) 2015; 20: 862–867.
Jiang J, Chen P, Chen J, et al. Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis. Atherosclerosis 2012; 224: 187–194.
McIntyre NJ, Chesterton LJ, John SG, et al. Tissue-advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol. 2010; 5: 51–55.
Mácsai E, Benke A, Kiss I. Skin autofluorescence and mortality in patients on peritoneal dialysis. Medicine (Baltimore) 2015; 94: e1933.
Li PK, Culleton BF, Ariza A. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol. 2013; 24: 1889–1900.
Dong J, Yang ZK, Chen Y. Older age, higher body mass index and inflammation increase the risk for new-onset diabetes and impaired glucose tolerance in patients on peritoneal dialysis. Perit Dial Int. 2016; 36: 277–283.
Jung HY, Jang HM, Kim YW, et al. Depressive symptoms, patient satisfaction, and quality of life over time in automated and continuous ambulatory peritoneal dialysis patients: A prospective multicenter propensity-matched study. Medicine (Baltimore) 2016; 95: e3795.
Mehrotra R, Devuyst O, Davies SJ, et al. The current state of peritoneal dialysis. J Am Soc Nephrol. 2016; 27: 3238–3252.